MUM.AU
Incannex Healthcare, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic · AU
Sep 9, 2026, 12:00 UTC
Incannex Healthcare commenced patient dosing in the DReAMzz Phase 2 dose-optimization study of IHL-42X for obstructive sleep apnea.
Source:Sep 9, 2026, 12:00 UTC
Incannex Healthcare was granted a U.S. composition and methods of treatment patent covering IHL-42X with baseline expiry in 2040.
Source:Jul 23, 2026, 12:00 UTC
Incannex Healthcare Inc. commenced participant screening in its DReAMzz Phase 2 dose confirmation study of IHL-42X for obstructive sleep apnea.
Source:Jun 25, 2026, 12:00 UTC
Incannex Healthcare Inc. received a U.S. patent grant from the USPTO for its IHL-42X composition and methods for treating Obstructive Sleep Apnea.
Source: